Modern Healthspan: CRISPR Therapy: Silencing PCSK9 Gene for Heart Health #shorts
Peer-Reviewed Research
Key Takeaways
- CRISPR-based PCSK9 therapy is in human trials for cardiovascular disease prevention.
- This approach epigenetically silences PCSK9 rather than blocking the protein like current drugs.
- Potential for one-time treatment instead of daily PCSK9 inhibitor medications.
- Phase 1 trial focuses on safety – effectiveness and durability still unknown.
Bottom Line
Watch for updates on this CRISPR therapy if you’re interested in long-term heart health solutions beyond daily medications. Ask your doctor about current PCSK9 inhibitor options if LDL cholesterol is a concern.
Explore More
- Modern Healthspan’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
- Gabrielle Lyon: What role does estrogen actually play in cardiovascular health?
- Max Lugavere: "We Should Be More Lenient of People Who Fart" - Dr. Trisha Pasricha
- Max Lugavere: This Numbers Means More Than Body Fat % - Dr. Gabrielle Lyon
- Michael Greger: One of the Most Effective Single Pieces of Advice for Weight Loss
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network